Cyprus
Cyprus is a sovereign island state in the eastern Mediterranean, situated south of Turkey and west of Syria and Lebanon. Administratively, the Republic of Cyprus is divided into six districts. The country operates as a presidential republic. Cyprus became a member of the European Union on 1 May 2004 and joined the Eurozone, adopting the euro as its currency, on 1 January 2008. As an EU and Eurozone member, Cyprus participates fully in the Single Market and aligns with EU legal and regulatory frameworks across economic, social, and health sectors.
Healthcare budget
1,5 € billion
Inhabitants
1,4 million
GDP per capita
$38.674
Currency
EUR (1 EUR = 1 EUR)
World Ranking
GDP 106th
Cypriot healthcare
Cyprus operates a universal health coverage system known as the General Healthcare System (GeSY), which aims to provide comprehensive health services to all citizens largely free at the point of use. The system is overseen by the Ministry of Health and implemented by the Health Insurance Organization (OAY), which functions as the central public insurer and coordinator of care within GeSY. Under the scheme, both public and private providers can participate under agreed reimbursement rates and contractual terms.
Healthcare services are funded through contributions from citizens and employers, with defined rates deducted from income, while access to primary care, specialists, and hospital services is facilitated without user charges or with nominal co-payments. A defined pharmacy fee applies per prescription item. Private healthcare remains available in parallel and funded through voluntary insurance and out-of-pocket payments, offering alternative access for patients choosing not to use GeSY contracted services.
Cypriot Pharmaceutical Environment
The pharmaceutical market in Cyprus is small, reflecting the country’s population of approximately 1.4 million. In 2023, Cyprus spent about €467 per capita on retail pharmaceuticals, below the EU average of approximately €510 per capita.
Cyprus operates a regulated pricing and reimbursement framework, including elements of external and internal reference pricing, with reimbursement administered by the Health Insurance Organization (HIO). Electronic prescribing is fully implemented, allowing centralized monitoring of prescribing and dispensing.
Domestic production is limited and the market remains largely dependent on imports. Pharmaceutical supply, particularly for public-sector and hospital needs, relies heavily on centralized, government-led tender-like procurement procedures, alongside distribution through private wholesalers and retail pharmacies.
Today’s challenges
Cyprus’s pharmaceutical environment is strongly influenced by its small population size and limited market volumes, which reduce commercial attractiveness and often lead to delayed launches or restricted availability of innovative medicines. Access to centrally authorized novel therapies remains lower than in many EU countries.
In practice, the small size of the healthcare community means that pharmaceutical promotion and uptake rely heavily on direct engagement, close professional networks, and personal relationships, while limited administrative capacity contributes to longer evaluation and access timelines.
The Cypriot expert
Theodore Kountanis
Challenge us with your case and we will show you the possibilities for your product.
Services
Distribution
We manage, through our logistic partners with their regional warehouses, the distribution to our region (26 countries). They have the capability to handle the most demanding of specialized product order management, storage, handling and distribution requirements.
Learn moreEarly Market Research
You know that market research is critical. It provides customer insights, competitive intelligence, behavioural tendencies, and product positioning. And market research increasingly is becoming an important component for linking R&D and marketing teams.
Learn moreMarket Access
Achieving reimbursement and getting the right price are the 2 most important drivers for a successful launch of an innovative pharmaceuticals in our part of Europe. Health Authorities in any European country decide individually based on their local regulations, policies, framework, social values and available health care budget.
Learn morePharmacovigilance
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.
Learn moreMarket Authorisation
Unlike other regions, in the EU a number of options is available to obtain a marketing authorisation. Centralised at the European Medicines Agency in Amsterdam or decentralised with the individual competent authorities of the member states, each marketing authorisation application procedure has its pros and cons.
Learn moreSales and Marketing
Entering the European market is not easy. Up to 51 countries with different healthcare systems. What is your strategy? Apart from the Big-5, what do you do with the other 26 countries? We offer a solution for 26 countries. Sales and marketing is our core business.
Learn more